公司概覽
業務類別 Biotechnology
業務概覽 Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
公司地址 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
電話號碼 +1 650 850-5070
傳真號碼 --
公司網頁 https://www.mazetx.com
員工數量 125
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Misbah Tahir Chief Financial Officer -- 02/09/2025
Ms. Courtney J. Phillips General Counsel and Corporate Secretary 美元 191.78K 31/03/2025
Mr. Atul Dandekar Chief Strategy and Business Officer -- 31/03/2025
Dr. Jason V. Coloma, PhD Chief Executive Officer and Director 美元 527.26K 31/03/2025
Ms. Amy Bachrodt Senior Vice Preisdent, Finance and Principal Accounting Officer -- 31/03/2025
Dr. Harold S. Bernstein President, Research and Development and Chief Medical Officer 美元 526.67K 31/03/2025
 
董事會成員
董事會 職務 更新日期
Dr. Richard H. Scheller, PhD Independent Director 31/03/2025
Mr. Herve Hoppenot Chairman of the Board 06/10/2025
Dr. Catherine Angell Sohn, Pharm.D. Independent Director 31/03/2025
Dr. Jason V. Coloma, PhD Chief Executive Officer and Director 31/03/2025
Dr. Nancy C. Andrews, M.D.,PhD Independent Director 31/03/2025
Mr. Neil Exter, M.B.A. Independent Director 31/03/2025
Dr. Sekar Kathiresan, M.D. Independent Director 31/03/2025
Mr. Daniel K. Spiegelman Independent Director 31/03/2025
Dr. Jonathan E. Lim,M.D. Independent Director 31/03/2025
 
所屬ETF (更新日期: 07/03/2026 02:09)
代號 名稱 佔比% 持有日期
VTHRVanguard Russell 3000 ETF0.004%31/01/2026
UWMProShares Ultra Russell20000.003%27/02/2026
URTYProShares UltraPro Russell20000.003%27/02/2026
VTWGVanguard Russell 2000 Growth ETF0.003%31/01/2026
AVSUAvantis Responsible US Equity ETF0.002%28/02/2026
ITWOProShares Russell 2000 High Income ETF0.002%27/02/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.002%28/02/2026
ESSCEventide Small Cap ETF0.002%27/02/2026
HDGProShares Hedge Replication0.00005%27/02/2026
ARWGArcher Growth ETF<0.000001%22/01/2026
GURUGlobal X Guru™ ETF<0.000001%27/02/2026
  1   2  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.